Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Abstract Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spontaneous and voluntary adverse event (AE) reports ha...
Những tác giả chính: | , , , , , , , , , , |
---|---|
Định dạng: | Bài viết |
Ngôn ngữ: | English |
Được phát hành: |
Adis, Springer Healthcare
2023-07-01
|
Loạt: | Rheumatology and Therapy |
Những chủ đề: | |
Truy cập trực tuyến: | https://doi.org/10.1007/s40744-023-00576-8 |